Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 20
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Tipo de documento
Intervalo de ano de publicação
1.
J Sports Sci Med ; 20(2): 328-338, 2021 06.
Artigo em Inglês | MEDLINE | ID: mdl-34211326

RESUMO

Sports nutrition supplements have previously been reported to contain undeclared doping substances. The use of such supplements can lead to general health risks and may give rise to unintentional doping violations in elite sports. To assess the prevalence of doping substances in a range of high-risk sports nutrition supplements available from Dutch web shops. A total of 66 sports nutrition supplements - identified as potentially high-risk products claiming to modulate hormone regulation, stimulate muscle mass gain, increase fat loss, and/or boost energy - were selected from 21 different brands and purchased from 17 web shops. All products were analyzed for doping substances by the UK life sciences testing company LGC, formerly known as the Laboratory of the Government Chemist, using an extended version of their ISO17025 accredited nutritional supplement screen. A total of 25 out of the 66 products (38%) contained undeclared doping substances, which included high levels of the stimulants oxilofrine, ß-methylphenethylamine (BMPEA) and N,ß-dimethylphenethylamine (NBDMPEA), the stimulant 4-methylhexan-2-amine (methylhexaneamine, 1,3-dimethylamylamine, DMAA), the anabolic steroids boldione (1,4-androstadiene-3,17-dione) and 5-androstene-3ß,17α-diol (17α-AED), the beta-2 agonist higenamine and the beta-blocker bisoprolol. Based upon the recommended dose and the potential variability of analyte concentration, the ingestion of some products identified within this study could pose a significant risk of unintentional doping violations. In addition to inadvertent doping risks, the prescribed use of 3 products (4.5%) could likely impose general health risks.


Assuntos
Suplementos Nutricionais/análise , Dopagem Esportivo , Contaminação de Medicamentos , Agonistas Adrenérgicos beta/análise , Antagonistas Adrenérgicos beta/análise , Alcaloides/análise , Anfetaminas/análise , Androstadienos/análise , Humanos , Prevalência , Medição de Risco , Congêneres da Testosterona/análise , Tetra-Hidroisoquinolinas/análise
2.
Clin Toxicol (Phila) ; 59(11): 975-981, 2021 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-33755516

RESUMO

BACKGROUND: Weight loss and sports supplements containing deterenol have been associated with serious adverse events including cardiac arrest. OBJECTIVE: To determine the presence and quantity of experimental stimulants in dietary supplements labeled as containing deterenol sold in the United States. METHODS: Dietary supplements available for sale in the US and labeled as containing deterenol or one of its synonyms (e.g., isopropylnorsynephrine and isopropyloctopamine) were purchased online. For each brand, one container or subsample was analyzed by NSF International (Ann Arbor, MI) and one container or subsample by the Netherland's National Institute for Public Health and the Environment (RIVM, Bilthoven, The Netherlands). When differences existed between the two containers or subsamples of the same brand, both products were reanalyzed by Sciensano (Brussels, Belgium). NSF International carried out qualitative and quantitative analyses using ultra-high-performance liquid chromatography (UHPLC) quadrupole-Orbitrap mass spectrometry. RIVM performed qualitative and quantitative analysis using UHPLC quadrupole time-of-flight mass spectrometry. Sciensano carried out qualitative analysis using UHPLC quadrupole-Orbitrap mass spectrometry. RESULTS: Seventeen brands of supplements were analyzed. Many brands included more than one prohibited stimulant in the same product: 4 brands (24%, 4/17) included 2 stimulants, 2 (12%, 2/17) combined 3 stimulants, and 2 (12%, 2/17) combined 4 stimulants. The range of quantities per recommended serving size of the 9 stimulants detected were 2.7 mg to 17 mg of deterenol; 1.3 mg to 20 mg of phenpromethamine (Vonedrine); 5.7 mg to 92 mg of beta-methylphenylethylamine (BMPEA); 18 mg to 73 mg of octodrine; 18 mg to 55 mg of oxilofrine; 48 mg of higenamine; 17 mg of 1,3-dimethylamylamine (1,3-DMAA); 1.8 mg to 6.6 mg of 1,3-dimethylbutylamine (1,3-DMBA); and 5.3 mg of 1,4-dimethylamylamine (1,4-DMAA). CONCLUSION: Weight loss and sports supplements listing deterenol as an ingredient contained 9 prohibited stimulants and 8 different mixtures of stimulants, with as many as 4 experimental stimulants per product. These cocktails of stimulants have never been tested in humans and their safety is unknown.


Assuntos
Agonistas Adrenérgicos/análise , Fármacos Antiobesidade/análise , Estimulantes do Sistema Nervoso Central/análise , Suplementos Nutricionais/análise , Agonistas Adrenérgicos/efeitos adversos , Alcaloides/análise , Aminas/análise , Anfetaminas/análise , Fármacos Antiobesidade/efeitos adversos , Estimulantes do Sistema Nervoso Central/efeitos adversos , Qualidade de Produtos para o Consumidor , Suplementos Nutricionais/efeitos adversos , Efedrina/análogos & derivados , Efedrina/análise , Heptanos/análise , Humanos , Octopamina/análogos & derivados , Octopamina/análise , Medição de Risco , Tetra-Hidroisoquinolinas/análise , Estados Unidos
3.
Chemosphere ; 198: 377-385, 2018 May.
Artigo em Inglês | MEDLINE | ID: mdl-29421753

RESUMO

In this study the occurrence and the behavior of illicit drugs and their metabolites have been investigated for two wastewater treatment plants (WWTPs) (namely, WWTP-1 and WWTP-2) located in Sicily (island of Italy). Samples were analyzed for methamphetamine, cocaine (COC), 3,4-methylenedioxymethamphetamine (MDMA), methadone (METH), 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), 3,4-methylenedioxy amphetamine (MDA); 3,4-methylenedioxy ethylamphetamine (MDEA), 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH) and Benzoylecgonine (BEG). The BEG, COC, MOR and THC-COOH were found at the highest concentration in both WWTPs. The Wastewater-based epidemiology calculation for BEG, COC, cannabinoids and THC-COOH was performed. On average, for both plants, population consumes 1.6 and 23.4 dose 1000 inh-1 day-1 of cocaine and cannabis, respectively. For WWTP-1 negative removals of illicit drugs were observed. For WWTP-2 the following average removal efficiencies were obtained: BEG (77.85%), COC (92.34%), CODEINE (64.75%), MOR (90.16%) and THC-COOH (68.64%).


Assuntos
Drogas Ilícitas/análise , Eliminação de Resíduos Líquidos , Águas Residuárias/química , Poluentes Químicos da Água/análise , Anfetamina/análise , Anfetaminas/análise , Canabidiol/análise , Cocaína/análogos & derivados , Cocaína/análise , Dronabinol/análise , Combinação de Medicamentos , Humanos , Metanfetamina/análise , Pirrolidinas/análise , Sicília , Detecção do Abuso de Substâncias
4.
Farm. comunitarios (Internet) ; 8(4): 26-33, dic. 2016. mapas, graf, tab
Artigo em Espanhol | IBECS | ID: ibc-159414

RESUMO

El objetivo del presente trabajo fue describir y analizar la situación en España de los productos de venta ilícita, tanto medicamentos como complementos alimenticios, poniendo en conocimiento las principales acciones realizadas en los últimos meses y su contextualización a nivel mundial. Asimismo, servir de alerta sobre la magnitud del problema y la importancia del papel del farmacéutico comunitario. Se realizó una búsqueda de información tanto a nivel nacional como internacional y se realizó un análisis descriptivo de las Notas Informativas de la Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) (medicamentos ilegales, uso humano, 2015). Los productos de venta ilícita representan un problema grave para la salud pública que no ha parado de aumentar. En España, en 2015 se publicaron 20 notas donde se prohibió y retiró un total de 35 productos. Dichos productos estaban comercializados como complemento alimenticio y presentaban un principio activo en cantidad suficiente para conferirle legalmente la condición de medicamento. El 86% se dirigía a la disfunción eréctil. Para minimizar este problema, es imprescindible la colaboración internacional, siendo la última y más importante operación PANGEA VIII, en junio del 2015, implicando a 115 países. En enero del 2016 entró en vigor la Convención Medicrime, tratado internacional sobre la falsificación de productos médicos y delitos similares. Por otro lado, también es necesario concienciar a la ciudadanía y dotarla de mecanismos para identificar el riesgo potencial. Los productos adquiridos fuera de los canales legales de distribución no aseguran el cumplimiento de las normas de correcta fabricación, distribución, ni posterior conservación y carecen de la información adecuada (AU)


The objective of this article was to describe and analyze the situation of illicit products in Spain, both medicines and dietary supplements, notifying main actions taken in recent months and their worldwide contextualization. Also serve as a warning about the magnitude of the problem and the importance of the role of the community pharmacist. Searches of information were looked at a national and international level. A descriptive analysis of the Information Notes published by the Spanish Agency of Medicines and Medical Devices (AEMPS, Illegal Drugs, Human Use, 2015) was also conducted. Illicit sale products constitute a major problem for public health that has not stopped increasing. Specifically, in Spain, 20 Notes were published in 2015. These included the prohibition and withdrawal of a total of 35 products. Marketed as dietary supplement, they contained an active ingredient enough to be legally considered as a medicine. 86% were aimed at treating erectile dysfunction. It is essential international collaboration to minimize this issue. The last and most important operation was PANGEA VIII in June 2015, which involved 115 countries. In January 2016, the «Medicrime Convention» entered into force, an international agreement on counterfeiting of medical products and similar crimes. In addition, it is necessary to raise awareness and provide the citizens with mechanisms to identify potential risks inherent to the illicit sale products. Products purchased outside the permitted distribution channels do not ensure compliance with good manufacturing practice, distribution or subsequent storage, and they lack of adequate information (AU)


Assuntos
Humanos , Masculino , Feminino , Lista de Medicamentos Potencialmente Inapropriados/classificação , Farmácias/classificação , Suplementos Nutricionais/classificação , Saúde Pública/métodos , Disfunção Erétil/diagnóstico , Anfetaminas/efeitos adversos , Pessoal de Saúde , Lista de Medicamentos Potencialmente Inapropriados/normas , Lista de Medicamentos Potencialmente Inapropriados , Suplementos Nutricionais/toxicidade , Saúde Pública/classificação , Espanha/etnologia , Disfunção Erétil/complicações , Anfetaminas/análise , Internet
5.
J Anal Toxicol ; 40(9): 726-731, 2016 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-27550994

RESUMO

Urine drug testing (UDT) has become an essential component in the management of patients prescribed opioid analgesics for the treatment of chronic non-malignant pain. Several laboratory methods are available to monitor adherence with the pharmacological regimen and abstinence from illicit or unauthorized medications. Immunochemical screening methods are rapid and economical, but they have limitations, including lack of specificity, and confirmatory methods are often necessary to verify presumptive positive results. We analyzed the results of confirmatory assays in an outpatient setting to determine the predictive value of presumptive positive urine drug screen results using an automated immunoassay for eight common drugs or drug classes. Positive predictive values (PPVs), in descending order, were as follows: cannabinoids (100%), cocaine (100%), opiates (86.8%), benzodiazepines (74.6%), oxycodone (67.6%), methadone (44.1%) and amphetamines (9.3%). The number of positive barbiturate results was too small to be included in the statistical analysis.


Assuntos
Analgésicos Opioides/análise , Analgésicos Opioides/urina , Avaliação Pré-Clínica de Medicamentos/métodos , Estudos Prospectivos , Anfetaminas/análise , Anfetaminas/urina , Analgésicos Opioides/economia , Barbitúricos/análise , Barbitúricos/urina , Benzodiazepinas/análise , Benzodiazepinas/urina , Canabinoides/análise , Canabinoides/urina , Dor Crônica/tratamento farmacológico , Cocaína/análise , Cocaína/urina , Cromatografia Gasosa-Espectrometria de Massas , Humanos , Imunoensaio , Metadona/análise , Metadona/urina , Alcaloides Opiáceos/análise , Alcaloides Opiáceos/urina , Oxicodona/análise , Oxicodona/urina , Espectrometria de Massas em Tandem
6.
Drug Test Anal ; 8(3-4): 328-33, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-25847603

RESUMO

The amphetamine isomer ß-methylphenylethylamine (BMPEA) was first synthesized in the early 1930s, but its efficacy and safety in humans has not been studied. Recently, the United States Food and Drug Administration (FDA) detected BMPEA in dietary supplements labelled as containing Acacia rigidula. Over a year after the FDA reported its findings, we analyzed Acacia rigidula dietary supplements to determine if BMPEA had been removed. Supplements were analyzed using liquid chromatography-quadrupole time-of-flight mass spectrometry. Diluted methanolic extract from each supplement was run three times and each data set obtained was analyzed using Agilent MassHunter Qualitative Analysis. The presence of BMPEA was confirmed by accurate mass, retention time and mass spectra match against a reference standard. Quantification of BMPEA was determined using an eight-point calibration curve of spiked standard to a matrix blank. Twenty-one brands of Acacia rigidula supplements were analyzed. More than half (11/21; 52.4%) of the Acacia rigidula supplement brands contained BMPEA. The stimulant was present at quantities such that consumers following recommended maximum daily servings would consume a maximum of 93.7 mg of BMPEA per day. Consumers of Acacia rigidula supplements may be exposed to pharmacological dosages of an amphetamine isomer that lacks evidence of safety in humans. The FDA should immediately warn consumers about BMPEA and take aggressive enforcement action to eliminate BMPEA in dietary supplements. Copyright © 2015 John Wiley & Sons, Ltd.


Assuntos
Acacia/química , Anfetaminas/isolamento & purificação , Estimulantes do Sistema Nervoso Central/isolamento & purificação , Suplementos Nutricionais/análise , Anfetaminas/análise , Estimulantes do Sistema Nervoso Central/análise , Cromatografia Líquida/métodos , Humanos , Espectrometria de Massas/métodos , Padrões de Referência , Estados Unidos , United States Food and Drug Administration
7.
Drug Test Anal ; 8(3-4): 344-50, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26015311

RESUMO

ß-Methylphenylethylamines are positional isomers of amphetamines and have been discovered in sporting supplements. Although the fragmentation of the ß-methylphenylethylamine and N-methyl-ß-methylphenylethylamine in gas chromatography-electron ionization-mass spectrometry (GC-EI-MS) systems is significantly different to their amphetamine and methylamphetamine isomers, under electrospray ionization commonly used in liquid chromatography-mass spectrometry (LC-MS) systems, the fragmentation of each of the isomeric pairs is almost identical. The similarities in fragmentation make it possible for the misidentification of the ß-methylphenylethylamines as the illicit amphetamines. It is proposed that the similarities are due to a fragmentation pathway involving a common phenonium ion intermediate. By careful control of fragmentation energies in liquid chromatography-tandem mass spectrometry (LC-MS/MS) systems and/or close examination of the relative abundances of product ions formed by collision-induced dissociation (qualifier ratios), it is possible to distinguish the ß-methylphenylethylamines from the amphetamines, even if significant retention time separation is not achieved. In liquid chromatography-electrospray ionization-quadrupole time of flight (LC-ESI-QTOF) systems the mass spectra of the ß-methylphenylethylamines are identical to their amphetamine isomers. In such systems, retention time separation of the isomers is critical to avoid misidentification. During this study ß-methylphenylethylamine and N-methyl-ß-methylphenylethylamine have been identified in commercially available sporting supplements and oral fluid samples taken during the course of road-side drugs-in-drivers and workplace testing programmes. Copyright © 2015 John Wiley & Sons, Ltd.


Assuntos
Anfetaminas/análise , Cromatografia Líquida/métodos , Suplementos Nutricionais/análise , Espectrometria de Massas por Ionização por Electrospray/métodos , Anfetaminas/química , Cromatografia Gasosa/métodos , Isomerismo , Detecção do Abuso de Substâncias/métodos , Espectrometria de Massas em Tandem/métodos
8.
Scand J Clin Lab Invest ; 75(2): 156-61, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25562730

RESUMO

AIM: Exhaled breath has recently been identified as a possible matrix for drug testing. This study explored the potential of this new method for compliance monitoring of patients being treated for dependence disorders. METHODS: Outpatients in treatment programs were recruited for this study. Urine was collected as part of clinical routine and a breath sample was collected in parallel together with a questionnaire about their views of the testing procedure. Urine was analyzed for amphetamines, benzodiazepines, cannabis, cocaine, buprenorphine, methadone and opiates using CEDIA immunochemical screening and mass spectrometry confirmation. The exhaled breath was collected using the SensAbues device and analyzed by mass spectrometry for amphetamine, methamphetamine, diazepam, oxazepam, tetrahydrocannabinol, cocaine, benzoylecgonine, buprenorphine, methadone, morphine, codeine and 6-acetylmorphine. RESULTS: A total of 122 cases with parallel urine and breath samples were collected; 34 of these were negative both in urine and breath. Out of 88 cases with positive urine samples 51 (58%) were also positive in breath. Among the patients on methadone treatment, all were positive for methadone in urine and 83% were positive in breath. Among patients in treatment with buprenorphine, 92% were positive in urine and among those 80% were also positive in breath. The questionnaire response documented that in general, patients accepted drug testing well and that the breath sampling procedure was preferred. CONCLUSION: Compliance testing for the intake of prescribed and unprescribed drugs among patients in treatment for dependence disorders using the exhaled breath sampling technique is a viable method and deserves future attention.


Assuntos
Testes Respiratórios/métodos , Detecção do Abuso de Substâncias/métodos , Adolescente , Adulto , Idoso , Anfetaminas/análise , Anfetaminas/urina , Buprenorfina/análise , Buprenorfina/urina , Cocaína/análogos & derivados , Cocaína/análise , Cocaína/urina , Usuários de Drogas , Expiração , Feminino , Humanos , Masculino , Metadona/análise , Metadona/urina , Metanfetamina/análise , Metanfetamina/urina , Pessoa de Meia-Idade , Morfina/análise , Morfina/urina , Derivados da Morfina/análise , Derivados da Morfina/urina , Cooperação do Paciente , Adulto Jovem
9.
Artigo em Inglês | MEDLINE | ID: mdl-22849359

RESUMO

Pharmaceutical adulterants are commonly found in herbal weight loss products, and analytical techniques for detecting these adulterants have become increasingly important to the public health community. Previously we reported a novel analytical method for the determination of adulterants in herbal formulations by capillary electrophoresis with contactless conductivity detection. The current study refines this previously described technique by testing if anxiolytics, diuretics, and laxatives interfered with the detection of anorectics and antidepressants. A survey of herbal weight loss products sold by compounding pharmacies in Brazil were analysed to determine the presence of pharmaceutical adulterants. A total of 106 herbal products, collected from 73 pharmacies in nine Brazilian states, were analysed for amfepramone, sibutramine, fenproporex, fluoxetine, paroxetine, sertraline and bupropion using the new analytical method. The method permitted the rapid and selective screening for the seven adulterants. Of the 106 weight loss products sampled, four (3.8%) were found to be adulterated by fenproporex or sibutramine. The adulterated samples were compounded by four different pharmacies located in three different Brazilian states. The novel capillary electrophoresis method we developed may be a useful tool for public health organisations tasked with analysing herbal weight loss products.


Assuntos
Fármacos Antiobesidade/química , Suplementos Nutricionais/análise , Contaminação de Alimentos , Inspeção de Alimentos/métodos , Preparações de Plantas/química , Anfetaminas/análise , Ansiolíticos/análise , Fármacos Antiobesidade/efeitos adversos , Antidepressivos/análise , Depressores do Apetite/análise , Brasil , Ciclobutanos/análise , Suplementos Nutricionais/efeitos adversos , Diuréticos/análise , Condutividade Elétrica , Eletroforese Capilar , Contaminação de Alimentos/prevenção & controle , Laxantes/análise , Preparações de Plantas/efeitos adversos
10.
Talanta ; 77(4): 1351-7, 2009 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-19084648

RESUMO

An integrated method of liquid chromatography-heated electrospray ionization/tandem mass spectrometry was evaluated for high throughput screening of various abused drugs in urine. Chromatographic analysis was performed on a C18 reverse phase column using a linear gradient of 10mM ammonium acetate containing 0.1% formic acid-methanol as mobile phase and the total separation time was 7 min. A simple and rapid sample preparation method used was by passing urine samples through a 0.22 microm PVDF syringe filter. The detection limits of the studied abused drugs in urine were from 0.6 ng mL(-1) (ketamine) to 9.0 ng mL(-1) (norcodeine). According to the results, the linear range was from 1 to 1200 ng mL(-1) with relative standard deviation (R.S.D.s) value below 14.8% (intra-day) and 24.6% (inter-day). The feasibility of applying the proposed method to determine various abused drugs in real samples was examined by analyzing urine samples from drug-abused suspects. The abused drugs including ketamines and amphetamines were detected in suspected urine samples. The results demonstrate the suitability of LC-HESI-MS/MS for high throughput screening of the various abused drugs in urine.


Assuntos
Avaliação Pré-Clínica de Medicamentos/métodos , Drogas Ilícitas/urina , Urinálise/métodos , Acetatos/análise , Anfetaminas/análise , Cromatografia/métodos , Cromatografia Líquida/instrumentação , Cromatografia Líquida/métodos , Avaliação Pré-Clínica de Medicamentos/instrumentação , Formiatos/análise , Humanos , Ketamina/análise , Metanol/análise , Reprodutibilidade dos Testes , Espectrometria de Massas por Ionização por Electrospray/instrumentação , Espectrometria de Massas por Ionização por Electrospray/métodos , Espectrometria de Massas em Tandem/instrumentação , Espectrometria de Massas em Tandem/métodos , Fatores de Tempo , Urinálise/instrumentação
11.
Anal Chim Acta ; 608(1): 95-103, 2008 Feb 04.
Artigo em Inglês | MEDLINE | ID: mdl-18206999

RESUMO

We tried to develop a library search system using a portable, attenuated total reflection Fourier transform infrared (ATR-FT-IR) spectrometer for on-site identification of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) tablets. The library consisted of the spectra from mixtures of controlled drugs (e.g. MDMA and ketamine), adulterants (e.g. caffeine), and diluents (e.g. lactose). In the seven library search algorithms, the derivative correlation coefficient showed the best discriminant capability. This was enhanced by segmentation of the search area. The optimized search algorithm was validated by the positive (n=154, e.g. the standard mixtures containing the controlled drug, and the MDMA/MDA tablets confiscated) and negative samples (n=56, e.g. medicinal tablets). All validation samples except for four were judged truly. Final criteria for positive identification were decided on the basis of the results of the validation. In conclusion, a portable ATR-FT-IR spectrometer with our library search system would be a useful tool for on-site identification of amphetamine-type stimulant tablets.


Assuntos
3,4-Metilenodioxianfetamina/análise , Anfetaminas/análise , Química Farmacêutica/métodos , N-Metil-3,4-Metilenodioxianfetamina/análise , Espectroscopia de Infravermelho com Transformada de Fourier/instrumentação , Espectroscopia de Infravermelho com Transformada de Fourier/métodos , Detecção do Abuso de Substâncias/instrumentação , Algoritmos , Cafeína/análise , Avaliação Pré-Clínica de Medicamentos , Desenho de Equipamento , Ketamina/análise , Lactose/análise , Software , Detecção do Abuso de Substâncias/métodos , Comprimidos
12.
J Mass Spectrom ; 43(4): 528-34, 2008 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-18035853

RESUMO

A reliable and accurate GC-MS method was developed that allows both mass spectrometric and chromatographic discrimination of the six aromatic positional isomers of trimethoxyamphetamine (TMA). Regardless of the trifluoroacetyl (TFA) derivatization, chromatographic separation of all the investigated isomers was achieved by using DB-5 ms capillary columns (30 m x 0.32 mm i.d.), with run times less than 15 min. However, the mass spectra of the nonderivatized TMAs, except 2,4,6-trimethoxyamphetmine (TMA-6), showed insufficient difference for unambiguous discrimination. On the other hand, the mass spectra of the TFA derivatives of the six isomers exhibited fragments with significant intensity differences, which allowed the unequivocal identification of all the aromatic positional isomers investigated in the present study. This GC-MS technique in combination with TFA derivatization, therefore, is a powerful method to discriminate these isomers, especially useful to distinguish the currently controlled 3,4,5-trimethoxyamphetmine (TMA-1) and 2,4,5-trimethoxyamphetmine (TMA-2) from other uncontrolled TMAs.


Assuntos
Anfetaminas/análise , Avaliação Pré-Clínica de Medicamentos/instrumentação , Avaliação Pré-Clínica de Medicamentos/normas , Cromatografia Gasosa-Espectrometria de Massas/métodos , Cromatografia Gasosa-Espectrometria de Massas/normas , Anfetaminas/química , Drogas Desenhadas/análise , Drogas Desenhadas/química , Avaliação Pré-Clínica de Medicamentos/métodos , Humanos , Isomerismo , Reprodutibilidade dos Testes
14.
Rapid Commun Mass Spectrom ; 15(23): 2221-6, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11746889

RESUMO

Rapid screening and identification of drug and other mixtures are possible using a novel ambient pressure high-resolution ion mobility (APIMS) orthogonal reflector time-of-flight mass spectrometer (TOFMS). Departing ions from the APIMS drift tube traversed a pressure interface between the APIMS and TOFMS where they were subjected to numerous gas collisions that could produce selective fragmentation. By increasing the accelerating field in the pressure interface region, the ions generated using water-cooled electrospray ionization (ESI) underwent collision-induced dissociation (CID). Mixtures of ESI ions were separated by APIMS based on their respective size-to-charge (s/z) ratios while CID and analysis of mass-to-charge (m/z) ratios occurred in the pressure interface and TOFMS. Product ions that were formed in this pressure interface region could be readily assigned to precursor ions by matching the mobility drift times. This process was demonstrated by the examination of a mixture of amphetamines and the resulting fragmentation patterns of the mobility-separated precursor ion species [M + H](+).


Assuntos
Anfetaminas/análise , Espectrometria de Massas por Ionização por Electrospray/métodos , Anfetaminas/química , Avaliação Pré-Clínica de Medicamentos/instrumentação , Avaliação Pré-Clínica de Medicamentos/métodos , Humanos , Pressão
15.
J Chromatogr A ; 780(1-2): 265-84, 1997 Sep 12.
Artigo em Inglês | MEDLINE | ID: mdl-9335131

RESUMO

The application of micellar electrokinetic capillary chromatography (MECC) to the analysis of illicit drug seizures is presented. Areas investigated include general screening and qualitative and, in some instances, quantitative analysis of various drugs, including heroin, opium, cocaine, amphetamines, LSD and anabolic steroids. Due to its high efficiency, high selectivity and general applicability, MECC is well suited for forensic drug analyses.


Assuntos
Eletroforese Capilar/métodos , Drogas Ilícitas/análise , Micelas , Detecção do Abuso de Substâncias/métodos , Anfetaminas/análise , Anabolizantes/análise , Cocaína/análise , Medicina Legal/métodos , Heroína/análise , Dietilamida do Ácido Lisérgico/análise , Ópio/análise
17.
Clin Chem ; 24(3): 507-11, 1978 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-630717

RESUMO

Analytical data from the clinical toxicology laboratory of a large urban hospital, the Los Angeles County--University of Southern California Medical Center, are reported for the year 1976 and are compared to similar data previously documented for the year 1972. Drugs assayed, number of tests requested, and number of positive results are collated. Data on 58 assays show that the overwhelming majority of the requests continue to be for those tests that were originally classified as tests with 4-h turn-around time in the patient-focused concept for a clinical toxicology service in 1972. Total workload increased by 70%. The number of patients on whom some toxicologic assay was requested doubled in spite of a decrease in the number of patients admitted to the hospital during this five-year period. The data show that assays for some socially and clinically significant drugs--ethanol diazepam, tricyclics, and phencyclidine--increased disproportionally while others remained relatively constant, or even decreased.


Assuntos
Hospitais Gerais , Toxicologia , Anfetaminas/análise , California , Etanol/análise , Humanos , Hipnóticos e Sedativos/análise , Ópio/análise , Salicilatos/análise , Transtornos Relacionados ao Uso de Substâncias/diagnóstico , Tranquilizantes/análise
18.
J Chromatogr ; 122: 85-105, 1976 Jul 07.
Artigo em Inglês | MEDLINE | ID: mdl-180040

RESUMO

This paper reviews the applications of high-pressure liquid chromatography (HPLC) to forensic problems, and discusses some of the developments that have taken place in the use of the technique in the Metropolitan Police Laboratory. Preparation of octadecyltrichlorosilane-modified silica is described and some of the chromatographic characteristics of this material are investigated. Applications of HPLC to the analysis of cannabis, opium alkaloids, amphetamine-related materials, LSD and polynuclear hydrocarbons are described.


Assuntos
Cromatografia Líquida de Alta Pressão , Medicina Legal , Alcaloides/análise , Anfetaminas/análise , Benzazepinas/análise , Cannabis/análise , Cocaína/análise , Heroína/análise , Dietilamida do Ácido Lisérgico/análise , Ópio/análise , Ácidos Ftálicos/análise , Compostos Policíclicos/análise , Dióxido de Silício , Solventes , Oligoelementos/análise
20.
Aviat Space Environ Med ; 46(10): 1297-8, 1975 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-1180796

RESUMO

With the increased emphasis on establishing the presence or absence of drugs associated with aircraft accidents and the fact that fragmentation of tissue may be a problem in investigating these accidents, the need arises for a rapid, sensitive, and specific toxicologic means for detecting drugs that may be present in nanogram concentrations and when only extremely limited quantities of specimens are avialable for study. The use of radioimmunoassay (RIA) for the detection of drugs (e.g., amphetamines, barbiturates, opiates, and methaqualone) in selected aircraft accident cases is presented.


Assuntos
Acidentes Aeronáuticos , Medicina Aeroespacial , Preparações Farmacêuticas/análise , Radioimunoensaio , Anfetaminas/análise , Barbitúricos/análise , Humanos , Metaqualona/análise , Ópio/análogos & derivados , Ópio/análise
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA